Paper41360893
Comparison of prevalence of fatty liver disease according to the different nomenclatures of NAFLD, MAFLD, and MASLD in a large Iranian Population-based study.
Isfahani MM and 4 others. Sci Rep, 2025. Cited by 2 papers, by iCite.
Cite this record
ConductScience Library. Comparison of prevalence of fatty liver disease according to the different nomenclatures of NAFLD, MAFLD, and MASLD in a large Iranian Population-based study. Papers, record 41360893. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41360893
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Comparison of prevalence of fatty liver disease according to the different nomenclatures of NAFLD, MAFLD, and MASLD in a large Iranian Population-based study.
- PubMed
Topics11
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Non-alcoholic Fatty Liver Disease | Major topic |
| Fatty Liver | Major topic |
| Humans | |
| Male | |
| Iran | |
| Female | |
| Prevalence | |
| Middle Aged | |
| Adult | |
| Cohort Studies | |
| Aged |
Source PubMed
References30
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 40016310 | Global burden of MAFLD, MAFLD related cirrhosis and MASH related liver cancer from 1990 to 2021. | Sci Rep | 2025 | https://conductscience.org/library/papers/40016310 | PubMed |
| 2 | 36626630 | The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. | Hepatology | 2023 | https://conductscience.org/library/papers/36626630 | PubMed |
| 3 | 36695773 | Validation of nonalcoholic fatty liver disease (NAFLD) related steatosis indices in metabolic associated fatty liver disease (MAFLD) and comparison of the diagnostic accuracy between NAFLD and MAFLD. | Eur J Gastroenterol Hepatol | 2023 | https://conductscience.org/library/papers/36695773 | PubMed |
| 4 | 38403071 | MASLD identifies patients with significant hepatic fibrosis and steatosis in fatty liver population. | Ann Hepatol | 2024 | https://conductscience.org/library/papers/38403071 | PubMed |
| 5 | 38234088 | Concordance between metabolic dysfunction-associated steatotic liver disease and nonalcoholic fatty liver disease. | Hepatol Res | 2024 | https://conductscience.org/library/papers/38234088 | PubMed |
| 6 | 29145581 | Prospective Epidemiological Research Studies in Iran (the PERSIAN Cohort Study): Rationale, Objectives, and Design. | Am J Epidemiol | 2018 | https://conductscience.org/library/papers/29145581 | PubMed |
| 7 | 37453612 | A new era for steatotic liver disease: Evaluating the novel nomenclature in the UK Biobank. | J Hepatol | 2024 | https://conductscience.org/library/papers/37453612 | PubMed |
| 8 | 38317478 | Deciphering the implications of MAFLD and MASLD definitions in the NAFLD population: results from a single-center biopsy study. | Chin Med J (Engl) | 2024 | https://conductscience.org/library/papers/38317478 | PubMed |
| 9 | 37363821 | A multisociety Delphi consensus statement on new fatty liver disease nomenclature. | Hepatology | 2023 | https://conductscience.org/library/papers/37363821 | PubMed |
| 10 | 38587293 | High Concordance Between Nonalcoholic Fatty Liver Disease and Metabolic Dysfunction-Associated Steatotic Liver Disease in the TARGET-NASH Real-World Cohort. | Am J Gastroenterol | 2024 | https://conductscience.org/library/papers/38587293 | PubMed |
| 11 | 30821159 | The PERSIAN Guilan Cohort Study (PGCS). | Arch Iran Med | 2019 | https://conductscience.org/library/papers/30821159 | PubMed |
| 12 | 37714381 | Clinical and histological features under different nomenclatures of fatty liver disease: NAFLD, MAFLD, MASLD and MetALD. | J Hepatol | 2024 | https://conductscience.org/library/papers/37714381 | PubMed |
| 13 | 19766548 | Hepatic steatosis index: a simple screening tool reflecting nonalcoholic fatty liver disease. | Dig Liver Dis | 2010 | https://conductscience.org/library/papers/19766548 | PubMed |
| 14 | 40287355 | Transitioning from NAFLD to MAFLD to MASLD in the Mexican population. | Rev Gastroenterol Mex (Engl Ed) | 2025 | https://conductscience.org/library/papers/40287355 | PubMed |
| 15 | 39564428 | Comparison of NAFLD, MAFLD, and MASLD Prevalence and Clinical Characteristics in Asia Adults. | J Clin Exp Hepatol | 2025 | https://conductscience.org/library/papers/39564428 | PubMed |
| 16 | 37822312 | The heated debate over NAFLD renaming: An ongoing saga. | Hepatol Forum | 2023 | https://conductscience.org/library/papers/37822312 | PubMed |
| 17 | 38076354 | Prevalence of Non-alcoholic Fatty Liver Disease in Iran: A Systematic Review and Meta-analysis. | J Clin Exp Hepatol | 2024 | https://conductscience.org/library/papers/38076354 | PubMed |
| 18 | 34871813 | An Observational Data Meta-analysis on the Differences in Prevalence and Risk Factors Between MAFLD vs NAFLD. | Clin Gastroenterol Hepatol | 2023 | https://conductscience.org/library/papers/34871813 | PubMed |
| 19 | 32278004 | A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. | J Hepatol | 2020 | https://conductscience.org/library/papers/32278004 | PubMed |
| 20 | 35562658 | Distribution of FIB-4 index in the general population: analysis of 75,666 residents who underwent health checkups. | BMC Gastroenterol | 2022 | https://conductscience.org/library/papers/35562658 | PubMed |
Cited by3
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 2 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42277871 | Higher adherence to the EAT-lancet diet is associated with reduced risk of metabolic dysfunction-associated steatotic liver disease: a 5-year middle eastern cohort study. | Diabetol Metab Syndr | 2026 | https://conductscience.org/library/papers/42277871 | PubMed |
| 42115302 | Association of general obesity, metabolically healthy obesity, and abdominal adiposity markers with elevated liver enzymes: a population-based study. | Sci Rep | 2026 | https://conductscience.org/library/papers/42115302 | PubMed |
| 42074043 | The HepG2 Cell Line as a Model for Studying Metabolic Dysfunction-Associated Steatotic Liver Disease. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/42074043 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41360893
GET https://conductscience.org/api/papers/v1/41360893/references?page=2